NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $86.15 +0.52 (+0.61 %) (As of 01/27/2020 06:07 AM ET) Add Compare Today's Range$85.42Now: $86.15▼$88.8850-Day Range$78.51MA: $85.03▼$91.1052-Week Range$62.88Now: $86.15▼$100.13Volume1.22 million shsAverage Volume1.21 million shsMarket Capitalization$15.48 billionP/E RatioN/ADividend YieldN/ABeta1.32 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN Previous Symbol CUSIP09061G10 CIK1048477 Webhttp://www.bmrn.com/ Phone415-506-6700Debt Debt-to-Equity Ratio0.27 Current Ratio3.77 Quick Ratio2.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio8,615.00 P/E GrowthN/A Sales & Book Value Annual Sales$1.49 billion Price / Sales10.38 Cash Flow$0.21 per share Price / Cash Flow402.42 Book Value$16.67 per share Price / Book5.17Profitability EPS (Most Recent Fiscal Year)($0.33) Net Income$-77,210,000.00 Net Margins-2.65% Return on Equity-1.35% Return on Assets-0.91%Miscellaneous Employees2,849 Outstanding Shares179,630,000Market Cap$15.48 billion Next Earnings Date2/20/2020 (Estimated) OptionableOptionable Receive BMRN News and Ratings via Email Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BMRN Rates by TradingView BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced its earnings results on Wednesday, October, 23rd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.25. The biotechnology company earned $461.10 million during the quarter, compared to analyst estimates of $455.78 million. BioMarin Pharmaceutical had a negative net margin of 2.65% and a negative return on equity of 1.35%. The firm's quarterly revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.07) earnings per share. View BioMarin Pharmaceutical's Earnings History. When is BioMarin Pharmaceutical's next earnings date? BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for BioMarin Pharmaceutical. What price target have analysts set for BMRN? 15 Wall Street analysts have issued 1 year price targets for BioMarin Pharmaceutical's stock. Their forecasts range from $77.00 to $158.00. On average, they expect BioMarin Pharmaceutical's stock price to reach $112.50 in the next year. This suggests a possible upside of 30.6% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical. What is the consensus analysts' recommendation for BioMarin Pharmaceutical? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 1 hold rating and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical. What are Wall Street analysts saying about BioMarin Pharmaceutical stock? Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock: 1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs — Vimizim and Kuvan — continue to do well, driven by strong demand trends. Its newest product, Palynziq is witnessing strong commercial uptake in the United States. BioMarin’s rare disease pipeline is also progressing well. The company filed regulatory applications for Valrox in late 2019 and targets the same for vosoritide in 2020. Growing pipeline focus on gene therapy agents is encouraging. Valrox, a gene therapy for hemophilia A, is anticipated to be transformational, if approved. However, any development setbacks related to its pipeline candidates can hurt the stock. Moreover, uneven quarterly product sales of Naglazyme and Vimzin, owing to infrequent ordering patterns in some ex-U.S. countries, are a concern. The stock has underperformed the industry in the past one year.<" (1/15/2020) 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019) Has BioMarin Pharmaceutical been receiving favorable news coverage? Headlines about BMRN stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for BioMarin Pharmaceutical. Are investors shorting BioMarin Pharmaceutical? BioMarin Pharmaceutical saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 8,700,000 shares, an increase of 14.3% from the December 31st total of 7,610,000 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is presently 6.0 days. Currently, 4.9% of the shares of the stock are sold short. View BioMarin Pharmaceutical's Current Options Chain. Who are some of BioMarin Pharmaceutical's key competitors? Some companies that are related to BioMarin Pharmaceutical include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN). What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's key executives? BioMarin Pharmaceutical's management team includes the folowing people: Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61) Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.61%), Scout Investments Inc. (0.22%), Rhenman & Partners Asset Management AB (0.12%), DNB Asset Management AS (0.05%), United Services Automobile Association (0.03%) and Gradient Investments LLC (0.02%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical. Which institutional investors are selling BioMarin Pharmaceutical stock? BMRN stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, CMH Wealth Management LLC, Ironsides Asset Advisors LLC, Gateway Investment Advisers LLC, United Services Automobile Association, Eqis Capital Management Inc., Wealthstreet Investment Advisors LLC and Schmidt P J Investment Management Inc.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical. Which institutional investors are buying BioMarin Pharmaceutical stock? BMRN stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Scout Investments Inc., DNB Asset Management AS, Pegasus Asset Management Inc., Gradient Investments LLC, Wedbush Securities Inc., Nisa Investment Advisors LLC and D.B. Root & Company LLC. View Insider Buying and Selling for BioMarin Pharmaceutical. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $86.15. How big of a company is BioMarin Pharmaceutical? BioMarin Pharmaceutical has a market capitalization of $15.48 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe.View Additional Information About BioMarin Pharmaceutical. What is BioMarin Pharmaceutical's official website? The official website for BioMarin Pharmaceutical is http://www.bmrn.com/. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected] MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 1,346 (Vote Outperform)Underperform Votes: 793 (Vote Underperform)Total Votes: 2,139MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: 52-Week High/Low Prices For Stock Selection
